Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Human nose offers hope for new antibiotic
nose
"The notion that human microflora may also be a source of antimicrobial agents is a new discovery."
Scientists say 'lugdunin' can fight multi-resistant pathogens
 
Bacteria in the human nose can produce a previously unknown antibiotic that is able to combat multi-resistant pathogens, according to scientists from the University of Tübingen in Germany.

The novel antibiotic is produced by Staphylococcus lugdunensis, which colonises in the human nose. Tests on mice have shown the substance, which has been named lugdunin, is effective against multi-resistant pathogens where classic antibiotics have ceased to work.

The human nasal cavity is the natural habitat for harmful Staphylococcus bacteria. But scientists found that when Staphylococcus lugdunensis is present in the nose, Staphylococcus aureus (MRSA) is rarely found.

Commenting on the novel discovery, study author Professor Andreas Peschel explained: "Normally antibiotics are formed only by soil bacteria and fungi. The notion that human microflora may also be a source of antimicrobial agents is a new discovery."

Scientists from the Institute of Organic Chemistry found lugdunin is made up of a previously unseen ring structure of protein blocks. It therefore establishes a new class of materials.

The issue of antibiotic resistance is one of increasing concern - infections caused by antibiotic resistant bacteria such as MRSA are among the leading causes of death globally.

Another of the study's authors, Dr Bernhard Krismer, said: "There are estimates that suggest that more people will die from resistant bacteria in the coming decades than cancer. The improper use of antibiotics strengthens this alarming development."

Many of the pathogens cannot be avoided as they are part of human microflora on skin and mucous membranes. For those with serious underlying illnesses and weakened immune systems, they pose a particular threat.

The research team's findings, which have been published in the journal Nature, offer new ways to find antibiotics and develop strategies for the prevention of infection. Future work will aim to find out whether lugdunin could be used in therapy. One possibility is to give patients at risk from MRSA a harmless lugdunin-forming bacteria to prevent infection.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.